Prognostic Role of Contraindicated Drugs in Hospitalized Patients with Decompensated Heart Failure

• Published in: The Journal of pharmacology and experimental therapeutics 2023-08, Vol.386 (2), p.205-211
• Main Authors: Parish, Olivia, Cannata, Antonio, Shamsi, Aamir, Jordan-Rios, Antonio, Albarjas, Mohammad, Piper, Susan, Scott, Paul, Bromage, Daniel, McDonagh, Theresa
• Format: Article
• Language: English
• Subjects: Aftercare; Anti-Inflammatory Agents; Heart Failure - drug therapy; Humans; Patient Discharge; Prognosis; Prospective Studies; United States
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.122.001413

Due to the ageing population, patients often present to the hospital with a high burden of comorbidities and polypharmacy. For patients admitted with decompensated heart failure (HF), the evidence on the effects of contraindicated drugs on long-term mortality is scarce. Therefore, we aimed to investigate the effect of contraindicated medications on outcomes of patients admitted with decompensated HF. We analyzed all consecutive patients from the National Heart Failure Audit admitted to two tertiary centers with acutely decompensated HF between April 2020 and October 2021. We included medication classes listed as contraindicated (class III) in the most recent European and American guidelines on the management of HF. The primary outcome measure was in-hospital mortality. The secondary outcome measure was overall mortality. Overall, 716 patients admitted with acute HF were included. One-fifth (n = 156, 21.8%) were on at least one contraindicated medication at admission. The prevalence of comorbidities was comparable between medication groups. During hospitalization, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with increased in-hospital mortality (29% versus 9%, P = 0.013). On multivariable analyses, NSAID use was independently associated with worse in-hospital mortality (hazard ratio, 6.86; 95% confidence interval, 1.61–25.5; P = 0.005). However, other contraindicated medications were not associated with adverse outcomes. Postdischarge, the use of erythropoietin during admission was associated with increased mortality (54% versus 31%, P = 0.031). NSAID use is associated with increased in-hospital mortality for patients admitted with acute HF. However, inpatient use of other contraindicated medications was not associated with adverse in-hospital outcomes. Further studies are needed to confirm these results in larger and prospective cohorts. Use of nonsteroidal anti-inflammatory drugs is associated with a worse in-hospital mortality in patients with decompensated heart failure. The prognostic role of other contraindicated medications remains still uncertain.